Table 1.

Criteria for Suspected Alzheimer’s Disease Pathology (SADP)

Must have CSF or Neuroimaging evidence of β-amyloidosis alone or β-amyloidosis and Neurodegeneration

Pathology	CSF Biomarker		Neuroimaging Biomarker
β-amyloidosis	Aβ1–42 < 459 pg/mL	-or-	PIB PET MCBP > 0.18
Neurodegeneration	t-tau > 339 pg/mL -or- p-tau181 >67 pg/mL	-or-	Hippocampal volume > −1.5 SDs